WO1997004312A1 - Compounds and methods related to parathyroid hormone-like protein - Google Patents
Compounds and methods related to parathyroid hormone-like protein Download PDFInfo
- Publication number
- WO1997004312A1 WO1997004312A1 PCT/US1996/010090 US9610090W WO9704312A1 WO 1997004312 A1 WO1997004312 A1 WO 1997004312A1 US 9610090 W US9610090 W US 9610090W WO 9704312 A1 WO9704312 A1 WO 9704312A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pthrp
- esbm
- sample
- antibodies
- epitope
- Prior art date
Links
- 102000043299 Parathyroid hormone-related Human genes 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 61
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 title description 18
- 150000001875 compounds Chemical class 0.000 title description 5
- 238000003556 assay Methods 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 36
- 230000027455 binding Effects 0.000 claims abstract description 31
- 230000009870 specific binding Effects 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 claims abstract description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000009918 complex formation Effects 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 230000005298 paramagnetic effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 101150071808 PTHLH gene Proteins 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229910001385 heavy metal Inorganic materials 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 13
- 238000012216 screening Methods 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000012491 analyte Substances 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000005170 neoplastic cell Anatomy 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000000148 hypercalcaemia Effects 0.000 description 3
- 208000030915 hypercalcemia disease Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000012309 immunohistochemistry technique Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100410199 Homo sapiens PTHLH gene Proteins 0.000 description 1
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the field of the invention is chemistry related to parathyroid hormone-like protein.
- Malignancy-associated hypercalcemia also referred to as humoral hypercalcemia of malignancy (HHM)
- HHM humoral hypercalcemia of malignancy
- Malignancy-associated hypercalcemia is frequently caused by the over expression of parathyroid hormone-like protein (also referred to in the literature as parathyroid hormone-related protein) (PTHRP) .
- PTHRP parathyroid hormone-related protein
- Parathyroid hormone-like protein stimulates bone resorption and the reabsorption of calcium in the kidneys so as to raise calcium levels in the blood to dangerous levels.
- Secretion of parathyroid hormone ⁇ like protein has been associated with tumors derived from numerous tissues, and PTHRP overexpression has been associated with many different types of cancer including renal, bladder, prostate, breast and ovarian cancer.
- a review of PTHRP can be found in Burtis, Clin. Chem. 38:2171-2183 (1992) .
- Human parathyroid hormone-like protein as determined by analysis of gene structure, consists of a 173 amino acid protein derived from a precursor molecule having a 36 amino acid leader sequence, a 1-139 amino acid protein and a 1-141 amino acid protein, as described in Suva, et al . , Science £32:893-896 (1987) and Magnin, et al . , Proc. Natl. Acad. Sci. USA 85:597-601 (1988) . Unless specifically indicated otherwise, the term "PTHRP” and "parathyroid hormone-like protein” as used herein refer to human PTHRP molecules. A review of the structure of parathyroid hormone-like protein and genes encoding parathyroid hormone-like protein can be found in, among other places, Burtis, Clin. Chem. 38:2171- 2183.
- parathyroid hormone ⁇ like protein Given the frequent overexpression of parathyroid hormone ⁇ like protein in neoplastic cells, and the pathogenic effects of the production of excess levels of parathyroid hormone-like protein, it is of interest to provide antibodies for the sensitive detection of parathyroid hormone-like protein, including specific peptides of the native molecules.
- the invention provides for many different compounds and methods relating to PTHRP.
- One aspect of the invention provides eptitope-specific binding molecules which are capable of specifically binding to at least one epitope on PTHRP 140- 173 or at least one epitope on PTHRP 109-141.
- the eptitope- specific binding molecules include antibodies produced by hybridomas having identifying numbers 1D5 and 9H7, respective ⁇ ly, and non-antibody molecules such as those prepared by molecular imprinting which have specificity similar to that of the antibodies.
- Other aspects of the invention provides target molecules which bind to the eptitope-specific binding molecules. Such target molecules include polypeptides consisting of amino acids 140-173 or 109-141 of PTHRP, or subsets thereof, and other non-peptide molecules.
- kits for the detection of PTHRP in neoplastic cells and in various fluids of the body, and for the diagnosis and monitoring various PTHRP-producing diseases.
- Still other aspects of the invention provide methods of treating neoplasms, such as those involving administering to a patient or to the fluids or tissues of a patient, in si tu or ex si tu, one or more different eptitope-specific binding molecules of the invention.
- the present invention exploits the surprising discovery that monoclonal antibodies raised in response to a peptide consisting of amino acid residues 140-173 of PTHRP and monoclonal antibodies raised in response to a peptide consisting of amino acid residues 109-141 of PTHRP, either alone or in combination, are able to detect PTHRP expressing neoplastic cells with a much higher sensitivity than other monoclonal antibodies that are capable of specifically binding to other regions of the PTHRP molecule, and that the detection of PTHRP with such monoclonal antibodies was better correlated with the presence of neoplasia, especially breast cancer and prostate cancer, than other PTHRP specific antibodies.
- One aspect of the invention provides eptitope-specific binding molecules which are specific for one or more epitopes present on PTHRP 140-173.
- Such molecules include various antibodies, and particularly the monoclonal antibodies produced by the hybridoma 1D5 which was produced in the laboratory of Dr. Leonard Deftos, University of California, San Diego, and the San Diego Veterans Affairs Medical Center.
- Antibodies with binding specificities similar to the monoclonal antibody produced by hybridoma 1D5 may be obtained by, among other methods, immunizing a mouse with PTHRP 140-173 and employing conventional hybridoma generation techniques.
- Antibodies with binding specificities similar to the monoclonal antibody produced by hybridoma 1D5 can be confirmed by performing binding assays against PTHRP 140-173 or other assays as described below.
- Another aspect of the invention provides antibodies specific for one or more epitopes present on PTHRP 109-141.
- Such molecules include various antibodies, and particularly the monoclonal antibodies produced by the hybridoma 9H7 which was produced in the laboratory of Dr. Leonard Deftos, University of California, San Diego, and the San Diego Veterans Affairs Medical Center.
- Antibodies with binding specificities similar to the monoclonal antibody produced by hybridoma 9H7 may be obtained by, among other methods, immunizing a mouse with PTHRP 109-141 and employing conventional hybridoma generation techniques.
- Antibodies with binding specificities similar to the monoclonal antibody produced by hybridoma 9H7 can be confirmed by performing binding assays against PTHRP 109-141 or other assays as described below.
- the term "antibody” includes conventional antibodies such as immunoglobulin G(IgG) and M(IgM), and also refers to various antibody-derived molecules that possess binding specificity that is similar to the binding specificity of the antibody from which they were derived.
- antibody-derived molecules include Fab fragments, Fabc fragments, Fab 1 fragments, F(ab') fragments, antibody fusion proteins, single-chain antibodies, diabodies, bifunctional antibodies, chimeric antibodies, CDR grafted humanized antibodies, and the like.
- the antibodies of the invention include both monoclonal and polyclonal antibodies produced from a variety of animals including rabbits, rats, mice, monkeys and the like.
- antibody derived molecules that posses binding specificity that is similar to the binding specificity of the antibody from which the derivative is derived and methods of making them can be found in, among other places, Borreback, Antibody Engineering: 2nd Edition. Oxford Press (1994), Winter and Milstein, Nature 311:293-299 (1991), and the like.
- the antibodies of the invention may vary in both immunoglobulin class and allotype. Techniques for the production of conventional and monoclonal antibodies can be found among other places, Harlowe and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988), Peter and Baumgarten, Monoclonal Antibodies. Springer- Verlag, New York, NY (1992) .
- Antibodies of the invention include various antibody derived molecules that may be initially isolated through in vi tro selection techniques such as the use of combinatorial libraries that is described by Huse, et al . , Science 256:1275-1281 (1989) and similar techniques for in vitro antibody screening. Such in vi tro selected molecules may be isolated by screening libraries with the target molecules of the invention.
- the term "eptitope-specific binding molecules” includes both antibodies as described above, and also various non-antibody molecules which have negligible structural homology to antibodies but still have the property of being able to specifically bind to PTHRP 140-173, PTHRP 104-143, or other subfragments derived from these peptides.
- non-antibody epitope-specific binding molecules include "molecular imprints". Descriptions of how to produce molecular imprints can be found in, many other places, taught in US Patent 5,110,833 (Mossbach) , 0' Shannessy et al . , Anal. Biochem. 177:144-149 (1989), Andersson et al . , J. Chromatog.
- Non- antibody epitope-specific binding molecules provided for herein may be substituted for the antibodies in the assays, kits, treatment protocols and other aspects of the invention.
- Another aspect of the invention provides various conjugates of the eptitope-specific binding molecules, such as those labeled with a detectable marker having a chemical or biological properties of interest.
- Markers of interest include radionuclides, (e.g., 131 I, 125 I, "Tc) , fluorophores, enzymes, chromophores, biotin, paramagnetic isotopes, colloidal gold, radio-opaque imaging compounds, and the like.
- Labeled antibodies of the invention find use in a variety of procedures including immunoassays and disease therapy.
- Another aspect of the invention provides hybridomas for the production of monoclonal antibodies of the invention.
- Such hybridomas include 1D5 and 9H7 and other hybridomas producing monoclonal antibodies with similar binding properties for PTHRP epitopes.
- hybridomas Techniques for the production of hybridomas are described, among other places, in Peter and Baumgarten, Monoclonal Antibodies, Springer-Verlag, New York, NY (1992) .
- Conventional techniques for the production of monoclonal antibodies may be conveniently adapted for the production of hybridomas of the invention.
- a mouse may be inoculated with PTHRP 140-173 or other target molecules of the invention containing the appropriate epitope or epitopes so as to provide suitable fusion partners for hybridoma formation and other hybridomas producing monoclonal antibodies with similar binding properties for PTHRP epitopes.
- Another aspect of the invention provides cells for the expression of the antibodies of the invention by recombinant DNA technology, i.e., cells that do not naturally produce the antibodies of the invention.
- the recombinant DNA expression of such antibodies may be effected through the use of polynucleotide sequences encoding such antibodies.
- the recombinant cells for the expression of the antibodies of the may be either prokaryotic or eukaryotic.
- General techniques for the recombinant production of antibodies are described in, among other places, in U.S. Patent 4,816,397 (Boss, et al . ) , U.S. Patent 4,816,567 (Cabilly, et al . ) , U.K. Patent GB 2,188,638 (Winter, et al . ) , and U.K. Patent GB 2,209,757. These general techniques for recombinant antibody production may be adapted to the antibodies of the invention by the person of ordinary skill in the art.
- Another aspect of the invention provides for polynucleo ⁇ tide sequences encoding antibodies of the invention as well as expression vectors for the expression of the antibodies encoded by such polynucleotides.
- Polynucleotides of the invention encoding antibodies of the invention may be readily obtained by using recombinant DNA cloning techniques that are well known to the person of ordinary skill in the art.
- genes encoding antibodies specific for PTHRP 140-173 may be isolated from hybridomas capable of producing such antibodies , e.g., hybridoma 1D5, by means of nucleic acid hybridization screening of hybridoma derived libraries or by performing PCR (polymerase chain reaction) .
- target molecules capable of specifically binding to the antibodies of the invention.
- target molecules include PTHRP 140-173, PTHRP 109-141, and subfragments and derivatives thereof.
- the target molecules may comprise peptide or non-peptide molecules, but are preferably peptides.
- a particularly preferred embodiment of a PTHRP 140-173 derived target molecule is the polypeptide PTHRP 140-173, which consists of amino acids 140-173 of PTHRP in the following sequence: Thr- Ala-Leu-Leu-Trp-Gly-Leu-Lys-Lys-Lys-Lys-Glu-Asn-Asn-Arg-Arg- Thr-His-His-Met-Gln-Leu-Met-Ile-Ser-Leu-Phe-Lys-Ser-Pro-Leu- Leu-Leu-Leu.
- a particularly preferred embodiment of a PTHRP 109-141 target molecule is the polypeptide PTHRP 109-141, consisting of amino acids 109-141 of PTHRP in the following sequence: Ser-Ala-Trp- Leu-Asp-Ser-Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu- Ser-Asp-Thr-Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-Arg-His.
- the invention provides target molecules that are derivatives of PTHRP 140-173 and PTHRP 109-141, respectively, wherein the derivatives comprise epitopes that are able to bind to the antigen recognition sites of antibodies produced by hybridomas having numbers 1D5 and 9H7, respectively, and other antibodies of the invention.
- derivatives include peptides comprising the amino acid sequence of PTHRP 140-173 or PTHRP 109-141, and further comprising additional amino acids.
- PTHRP 140-173 and PTHRP 109-141 derivatives that are target molecules of the invention also include polypeptides that comprise less than the complete amino acid sequences of PTHRP 140-173 or PTHRP 109-141, respectively, and other splice variants.
- PTHRP 140- 173 derivatives that comprise less than the complete amino acid sequence of PTHRP 140-173 may easily be obtained by systematically producing polypeptides that consist of subregions of PTHRP 140-173 and testing such subregions for the property of specifically binding to antibodies produced by hybridoma 1D5 or other antibodies of the invention.
- the target molecules of the invention also include PTHRP 140-173 derivatives in which one or more amino acid residue of PTHRP 140-173 is substituted by a different amino acid residue.
- amino acid residue substitutions are conservative replacements, i.e, amino acid residues are substituted with amino acid residue with side chains having similar chemical properties, e.g., valine is substituted with alanine, leucine is substitute with isoleucine, etc.
- the invention similarly provides for additional PTHRP 109-141 derived target molecules .
- the invention provides for numerous antibodies, target molecules, and assays.
- Target molecules of the invention may be identified by conventional immunological techniques such as antibody binding assays, e.g., competition for binding between PTHRP 140-173 and monoclonal antibodies produced by hybridoma 1D5 or other antibodies (monoclonal or polyclonal) produced in response to PTHRP 140-173.
- Target molecules of the invention may be isolated by a variety of screening methods well known to the person of ordinary skill in the art, wherein the screening method employs the antibodies of the invention. Such methods include the screening of random peptide libraries or libraries of peptide variants derived from PTHRP 140-173 or PTHRP 109- 141. Detailed description of methods of screening libraries for peptides can be found in, among other places, in Clackson and Wells, Trends in Biotech.
- the libraries screened for target molecules of the invention may be in vi tro synthesized libraries or may involve the use of phage libraries.
- Screening for target molecules may also be accomplished by the screening of libraries of diverse peptides with the antibodies of the invention, e.g., antibodies produced by hybridomas 9H7 and 1D5.
- the screening of diverse libraries of molecules with antibodies of the invention may be applied to non-peptide molecule libraries so as to isolate non-peptide molecules that specifically bind to the antibodies of the invention.
- the generation and screening of non-peptide libraries is described in, among other places, Devlin et al . , Science 249:404-406 (1990), Kay et al . , Gene 128:59-65 (1993), Scott et al . , Proc. Natl. Acad. Sci. USA 89:5398-5402 (1992), Oldenburg, Proc. Natl.
- PTHRP 140-173 and PTHRP 109-143 may be determined (at least in part) by techniques such as nuclear magnetic resonance (NMR) and x-ray crystallography.
- NMR nuclear magnetic resonance
- Three- dimensional structural information of PTHRP 140-173 and PTHRP 109-141 may be used by the person of ordinary skill to design various derivatives of PTHRP 140-173 and PTHRP 109-141, respectively.
- PTHRP 140-173 and PTHRP 109-141 may be produced in vi tro by conventional solid phase polypeptide synthesis techniques, such as those described in the Bodanszky, Peptide Chemistry: A Practical Textbook, Springer-Verlag, New York, NY (1988), and Bailey, An Introduction To Peptide Chemistry, John Wiley & Sons, New York, NY (1992) .
- Machines for the automated synthesis of polypeptides having desired amino acid sequences are commercially available from many suppliers, e.g., Applied Biosystems, and may be used to produce target molecules of the invention that are peptides.
- PTHRP 140-173, PTHRP 109-141, and other target molecules of the invention may be produced by enzymatically or chemically cleaving PTHRP (produced naturally or by recombinant DNA technology) into smaller polypeptide fragments. Additionally, PTHRP 140-173, PTHRP 109-141, and other target molecules of the invention may also be produced by well-known recombinant DNA techniques, such as those described in Goedel, Gene Expression Technology, Methods In Enzymology Volume 185. Academic Press, San Diego (1991) .
- the target molecules of the invention have a number of uses that are apparent to the person of ordinary skill in the art.
- the target molecules of the invention may be used in immunoassays for the detection PTHRP.
- Target molecules of the invention may also be used produce the PTHRP- specific antibodies of the invention.
- Such antibodies may be produced by conventional procedures for the production of monoclonal antibodies or polyclonal antibodies, wherein an animal is injected with target molecules of the invention so as to induce the production of antibodies specific for the carboxy terminus of PTHRP.
- Another aspect of the invention provides assays for the detection of PTHRP.
- the term "assay” as used herein is used to refer both to a method of performing an assay and the physical assay device (and/or assay reagents) .
- the assays and assay methods provided by the invention include numerous immunoassays that have been specifically adapted for use with the antibodies and/or antibody molecules of the invention. Immunoassays may involve the use of pairs of molecules that can specifically bind to one another with high affinity and specificity. Typical of such specific binding pairs of molecules are an antibody and a molecule recognized by the binding sites on the antibody, e.g., the analyte.
- Immunoassays involve the measurement of the formation of (or lack of formation) complexes between the members of a specific binding pair of molecules, e.g., an antibody and an analyte recognized by the antibody.
- the immunoassay may detect analyte directly, i.e., in which complex formulation occurs between an antibody and the analyte so as to produce a signal that directly correlates with analyte concentration.
- Analyte concentration also may be detected by measuring the inhibition of complex formation, wherein the analyte of interferes with the formation of detectable complexes.
- the antibodies and target molecules of the invention may be used as the specific binding pair components in a variety of immunoassays, including but not limited to, ELISA, radioimmunoassays (RIA) , EMIT® assays, IRMA, two-site and the like.
- immunoassays including but not limited to, ELISA, radioimmunoassays (RIA) , EMIT® assays, IRMA, two-site and the like.
- a preferred embodiment of the assays of the invention are sandwich type assays in which one of the antibodies in the sandwich is a PTHRP 140-173 specific antibody of the invention and the other antibody in the "sandwich" is a PTHRP 109-141 specific antibody of the invention.
- Sandwich type assays employ a first antibody to bind analyte to a solid support (including paramagnetic beads and microtitre dishes) or the like and a second antibody that has the property of binding to analyte bound by the first antibody. The amount of bound second antibody may be measured so as to provide for the quantitation of the analyte in a solution.
- antibodies for use in a sandwich assay are the antibodies produced by hybridoma 1D5 and hybridoma 9H7, when used in combination with one another.
- Detailed protocols for some of the many immunoassays that may readily be adapted for use with the antibodies and/or antibody binding molecules of the invention can be found in D. Catty, Antibodies: A Practical Approach Volumes 1 and 2, IRL (1989), T. Chard, An Introduction To Radioimmunoassay and Related Techniques, Elsevier Press (1990), J. Clausen, Immunochemical Techniques For The Identification and Estimation Of Macromolecules: Laboratory Techniques In Biochemistry and Molecular Biology 3rd Ed. , Elsevier Science Publishers (1988), and the like.
- the assays of the invention may be either quantitative or qualitative.
- assays are performed which detect DNA or RNA coding for 1-173 splice variants of PTHRP.
- assays for performing such detection can be performed using standard procedures, and fall well within the ordinary skill of the art.
- the invention also provides for in vivo diagnostic assays wherein one or more antibodies or other eptitope-specific binding molecules of the invention are administered to a subject.
- antibodies are labeled with a detectable marker to provide for the detection of cells to which the labeled antibodies of the invention have bound, examples of such labels include radionuclides and radio-opaque imaging agents.
- Such methods of diagnosis may comprise the step of administering detectably labeled antibodies to a subject, whereby complexes between the antibody and PTHRP form, and the step of detecting such complexes.
- the assays of the invention may be either in vi tro or in vivo .
- the assays of the invention also include assays for the detection of PTHRP expressing cells by immunohistochemistry techniques such as those techniques described in Cuello Immunohistochemistry II, John Wiley & Sons (1993) , Bullock, et al . , Techniques In Immunocytochemistry Volumes 1 and 2. Academic Press (1983) , wherein the antibodies bound to PTHRP may be visualized by fluorescence or similar techniques.
- Immunohistochemistry techniques may comprise the step of incubating a tissue sample with a labeled antibody (labeled either directly or indirectly) of the invention and detecting where in the tissue sample the antibody binds by means of the label.
- the assays comprise the step of adding an antibody to a sample for analysis and measuring the binding of the antibody to the
- PTHRP in the sample for analysis may be may be labeled directly or indirectly.
- PTHRP in the sample for analysis interferes with the binding of the antibody of the invention to PTHRP of a target molecule of the invention.
- the antibodies of the invention may also be used in conjunction with flow cytometry so as to identify PTHRP producing or non-producing cells.
- kits for performing one or more of the various aspects of the invention may contain one or more reagents necessary for performing the immunoassays of the invention, and may contain the subject compounds and reagents in pre- measured amounts so as to ensure both precision and accuracy when performing the subject methods. Kits may also contain instructions for performing the methods of the invention.
- the kits of the invention may include one or more of the following items: antibodies of the invention, target molecules of the invention, standards of known concentration, buffers, antibody labeling reagents, reaction vessels, and the like.
- kits of the invention comprise at least two reagents that may be used in performing the subject assays.
- Kits for performing the sandwich assay may comprise an antibody of the invention having the property of specifically binding PTHRP 109-141, and an antibody of the invention having the property of specifically binding PTHRP 140-173.
- the kits of the invention may further comprise a target molecule of the invention.
- the antibodies and target molecules included in the subject kits may be labeled with a detectable marker.
- the kits of the invention may also comprise various other reagents useful for carrying out the assays of the invention, such reagents include buffers, solid supports, enzymatic substrates, secondary labeling antibodies, positive controls for PTHRP, negative controls for PTHRP, and the like.
- Treatment methods may include the administration of an effective amount of one or more of the eptitope-specific binding molecules of the invention, including PTHRP specific antibody.
- Such eptitope-specific binding molecules may be labeled or unlabeled, and may be complexed with a therapeutic agent such as a toxin, a radionuclide, an anti-cancer drug, and the like.
- Antibodies of the invention for therapeutic use are preferably antibodies derived from the same species as the species of the animal to be treated.
- the PTHRP specific antibodies to be administered to the patient are preferably human antibodies or "humanized” antibodies, e.g. CDR-grafted antibodies as described in Winter US patent 5,225,539 or chimeric antibodies as described in European patent application EP120694 (CellTech) .
- the invention also provides methods of treatment wherein antibodies or epitope-specific binding molecules are used to remove or "inactivate" PTHRP in the general circulation thereby reducing the hypercalcemia associated with PTHRP secretion.
- Another aspect of the invention provides pharmaceutical formulations comprising the antibodies or other eptitope- specific binding molecules of the invention.
- the subject pharmaceutical formulations may be used for both treatment and in vivo diagnosis, depending upon the precise formulation.
- the antibodies of the invention may be administered by a number of methods e.g., topically, orally, intranasally, by injection or by inhalation.
- the antibodies of the invention may also be used with one or more inert carrier materials.
- the preferred formulations of the invention are optimized for parenteral administration.
- the formulations may comprise an aqueous solution of a water soluble pharmaceutically acceptable salt of the active acids according to the invention, desirably in a concentration of 0.05 - 10%, and optionally also a stabilizing agent and/or buffer substances in aqueous solution. Dosage units of the solution may advantageously be enclosed in ampoules.
- the dosage at which the antibodies of the invention are administered may vary within a wide range and will depend on various factors such as, for example, whether or not the antibody is being used for diagnosis or therapy, the severity of the disease, the age of the patient, the binding affinity of the particular antibody for PTHRP, etc., and may have to be individually adjusted.
- a possible starting range for the amount of antibody which may be administered per day is about 0.001 mg to about 200 mg.
- excess PTHRP is removed from a patient by removing blood from the body, treating the blood with antibodies to remove PTHRP, and reintroducing the treated blood into the body.
- a container or bead, preferably plastic, is treated with antibody, preferably monoclonal, to epitope amino acid 140-173 of parathyroid hormone-like protein causing the antibody to adsorb to the surface of the container or bead.
- a serum sample containing an unknown level of parathyroid-like hormone is added to the coated container or bead along with a labeled derivative, preferably monoclonal, to epitope amino acid 109- 141 of parathyroid hormone-like protein.
- the mixture is incubated to allow complexation of the two antibodies and the parathyroid hormone-like protein, the solid phase is washed to remove uncomplexed material and the label detected.
- the signal is directly proportional to the parathyroid hormone ⁇ like protein level of the serum sample, and when compared to calibrators of known concentration, a specific determination of the parathyroid hormone-like protein level can be made.
- a competitive assay may be used, as for example, one in which labeled parathyroid hormone-like protein or a peptide of the 140-173 epitope can be added to the above described solid phase and serum sample.
- the endogenous parathyroid hormone-like protein compete with this labeled material to bind to the solid phase.
- the amount of parathyroid hormone-like protein in the sample which is inversely proportional to the signal detected, can be determined using a calibration curve of known parathyroid hormone-like protein concentrations.
- Both of the above example methods can be accomplished in the liquid phase with subsequent binding or precipitation to separate antibody bound label.
- the solid phase may or may not be paramagnetic.
- experiments were performed in which monoclonal antibodies raised against different portions of PTHRP were tested for their ability to detect PTHRP in neoplastic cells.
- the antibodies tested were prepared in response to the peptides consisting of amino acid residues 1- 34 of PTHRP, 109-141 of PTHRP, and 140-173 of PTHRP.
- the monoclonal antibodies were obtained from the laboratory of Dr. Leonard Deftos, University of California, San Diego, Veterans Administration Hospital.
- the PTHRP 109-141 specific antibody was produced by hybridoma 9H7.
- the PTHRP 140-173 specific antibody was produced by hybridoma 1D5.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09506668A JP2000513201A (en) | 1995-07-20 | 1996-06-10 | Compounds and methods related to parathyroid hormone-like proteins |
AU61721/96A AU6172196A (en) | 1995-07-20 | 1996-06-10 | Compounds and methods related to parathyroid hormone-like protein |
EP96919368A EP0871883A1 (en) | 1995-07-20 | 1996-06-10 | Compounds and methods related to parathyroid hormone-like protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50444495A | 1995-07-20 | 1995-07-20 | |
US08/504,444 | 1995-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997004312A1 true WO1997004312A1 (en) | 1997-02-06 |
Family
ID=24006283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/010090 WO1997004312A1 (en) | 1995-07-20 | 1996-06-10 | Compounds and methods related to parathyroid hormone-like protein |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0871883A1 (en) |
JP (1) | JP2000513201A (en) |
KR (1) | KR19990035755A (en) |
AU (1) | AU6172196A (en) |
WO (1) | WO1997004312A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085784A2 (en) * | 2000-05-12 | 2001-11-15 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF |
WO2004016151A2 (en) * | 2002-08-15 | 2004-02-26 | Osteotrophin, Llc | Pthrp-derived modulators of smooth muscle proliferation |
US7358355B2 (en) | 1996-09-26 | 2008-04-15 | Chugai Seiyaku Kabushiki Kaisha | Antibodies against human parathyroid hormone related protein |
WO2009023961A1 (en) * | 2007-08-17 | 2009-02-26 | Biochrom Pharma Inc. | Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US7727526B2 (en) | 2002-07-05 | 2010-06-01 | Universite Louis Pasteur | Use of PTHrP antagonists for treating renal cell carcinoma |
GB2471693A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | Parathyroid hormone related protein antagonists |
US8293479B2 (en) * | 2002-05-02 | 2012-10-23 | Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center | Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies |
US8501929B2 (en) | 2007-08-17 | 2013-08-06 | Biochrom Pharma Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
-
1996
- 1996-06-10 KR KR1019980700411A patent/KR19990035755A/en not_active Application Discontinuation
- 1996-06-10 EP EP96919368A patent/EP0871883A1/en not_active Withdrawn
- 1996-06-10 JP JP09506668A patent/JP2000513201A/en active Pending
- 1996-06-10 AU AU61721/96A patent/AU6172196A/en not_active Abandoned
- 1996-06-10 WO PCT/US1996/010090 patent/WO1997004312A1/en not_active Application Discontinuation
Non-Patent Citations (6)
Title |
---|
BIOCHEMISTRY, Volume 33, Number 23, issued 14 June 1994, YANG et al., "Parathyroid Hormone-Related Protein: Evidence for Isoform- and Tissue-Specific Posttranslational Processing", pages 7460-7469. * |
CANCER RESEARCH, Volume 53, Number 8, issued 15 April 1993, IWAMURA et al., "Immunohistochemical Localization of Parathyroid Hormone-Related Protein in Human Prostate Cancer" pages 1724-1726. * |
CHEMICAL ABSTRACTS, Volume 118, Number 15, issued 12 April 1993, KASAHARA et al., "Immunoassay of Parathyroid Hormone-Related Protein (PTHrP) in Body Fluid for Diagnosis", page 180, Abstract No. 118:140690e. * |
CLINICAL CHEMISTRY, Volume 38, Number 11, issued 1992, BURTIS, "Parathyroid Hormone-Related Protein: Structure, Function and Measurement", pages 2171-2183. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 85, issued January 1988, MANGIN et al., "Identification of a cDNA Encoding a Parathyroid Hormone-Like Peptide from a Human Tumor Associated with Humoral Hypercalcemia of Malignancy", pages 597-601. * |
THE NEW ENGLAND JOURNAL OF MEDICINE, Volume 322, Number 16, issued 19 April 1990, BURTIS et al., "Immunochemical Characterization of Circulating Parathyroid Hormone-Related Protein in Patients with Humoral Hypercalcemia of Cancer", pages 1106-1112. * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7358355B2 (en) | 1996-09-26 | 2008-04-15 | Chugai Seiyaku Kabushiki Kaisha | Antibodies against human parathyroid hormone related protein |
US7842790B2 (en) | 1996-09-26 | 2010-11-30 | Chugai Seiyaku Kabushiki Kaisha | Antibodies against human parathyroid hormone related protein |
WO2001085784A3 (en) * | 2000-05-12 | 2002-04-04 | Ist Naz Stud Cura Dei Tumori | POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF |
WO2001085784A2 (en) * | 2000-05-12 | 2001-11-15 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF |
US8293479B2 (en) * | 2002-05-02 | 2012-10-23 | Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center | Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies |
US7727526B2 (en) | 2002-07-05 | 2010-06-01 | Universite Louis Pasteur | Use of PTHrP antagonists for treating renal cell carcinoma |
WO2004016151A3 (en) * | 2002-08-15 | 2004-04-29 | Osteotrophin Llc | Pthrp-derived modulators of smooth muscle proliferation |
WO2004016151A2 (en) * | 2002-08-15 | 2004-02-26 | Osteotrophin, Llc | Pthrp-derived modulators of smooth muscle proliferation |
WO2009023961A1 (en) * | 2007-08-17 | 2009-02-26 | Biochrom Pharma Inc. | Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US7897139B2 (en) * | 2007-08-17 | 2011-03-01 | Biochrom Pharma, Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US8501929B2 (en) | 2007-08-17 | 2013-08-06 | Biochrom Pharma Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US20140220022A1 (en) * | 2007-08-17 | 2014-08-07 | Biochrom Pharma Inc. | Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
AU2008288645B2 (en) * | 2007-08-17 | 2017-02-02 | Biochrom Pharma Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US10463726B2 (en) | 2007-08-17 | 2019-11-05 | Biochrom Pharma Inc. | Method of inhibiting cancer in a mammal by administering an antibody to PTHrP |
GB2471693A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | Parathyroid hormone related protein antagonists |
Also Published As
Publication number | Publication date |
---|---|
AU6172196A (en) | 1997-02-18 |
KR19990035755A (en) | 1999-05-25 |
JP2000513201A (en) | 2000-10-10 |
EP0871883A1 (en) | 1998-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1303496C (en) | Ck-mm myocardial infarction immunoassay | |
JP2008513536A (en) | Monoclonal antibody against progastrin | |
US20120264149A1 (en) | Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method | |
JPH09512630A (en) | Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation | |
US5288614A (en) | Method for the detection of malignant diseases | |
US6642007B1 (en) | Assays for measurement of type II collagen fragments in urine | |
JP4334065B2 (en) | Reduction of immunoassay interference by substances derived from the framework regions of antibodies. | |
JP2005510696A (en) | Immunoassay and immunoassay kit for rapid and simultaneous detection of biochemical labels in patient samples | |
EP0871883A1 (en) | Compounds and methods related to parathyroid hormone-like protein | |
US20080293161A1 (en) | Detection of Carbohydrate Biomarkers | |
WO1997008551A1 (en) | Methods and antibodies for detecting creatine kinase | |
WO2012092175A1 (en) | Monoclonal antibodies against alpha-actinin-4 antigens, and uses therefor | |
US20030138975A1 (en) | Diagnostic signal amplification with proteinoid microspheres | |
JP4414023B2 (en) | Method and reagent for measuring arthritis-related melanotransferrin | |
WO2023061388A1 (en) | Immunoassay of galectin-3 | |
WO1997008549A1 (en) | Method for detecting kidney diseases, diagnostic drug therefor, and diagnostic kit therefor | |
EP0803065B1 (en) | A-protein as a diagnostic of cancer | |
JP2003501444A (en) | Hybridoma for lung cancer marker and monoclonal antibody specific to the marker | |
AU2002346529B2 (en) | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | |
WO2005106495A1 (en) | Procollagen ii biomarkers and methods | |
JPH0643167A (en) | Cancer marker tenascin and its determining method | |
JP2020148557A (en) | Method for measuring hmgb1 in sample and measurement reagent | |
WO2007126160A1 (en) | Prostasin partial peptide and anti-prostasin antibody | |
JPH07196698A (en) | Anti-human phospholipase a2-activated protein antibody and hybridoma producing the same and reagent for assaying human phospholipase a2-activated protein using the same and assay | |
JP2000227432A (en) | Prognostic examination of pulmonary cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1997 506668 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996919368 Country of ref document: EP Ref document number: 1019980700411 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996919368 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996919368 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980700411 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980700411 Country of ref document: KR |